Core Viewpoint - Baxter International (BAX) is positioned for growth due to the demand for its essential medical products and ongoing transformational actions, although inflationary pressures remain a concern [1] Company Performance - BAX shares have decreased by 12.4% year-to-date, while the industry has grown by 3.1% and the S&P 500 Index has increased by 11.6% [1] - The company reported revenues of $3.59 billion in the first quarter, reflecting a 2% increase on a reported basis and a 3% increase at constant currency [5] Market Dynamics - Demand for Baxter's products has shown a sustained recovery in 2023, driven by increasing hospital admissions and procedural volumes, as well as higher capital spending by hospitals expected in 2024 [3] - The Care & Connectivity Solutions category experienced a decline, primarily due to softness in the U.S. primary care market, but is anticipated to return to growth in the second half of the year [3] Transformational Actions - Baxter is completing transformational actions aimed at creating a more resilient supply chain and aligning with its manufacturing footprint by mid-2024 [4] - The company divested its BioPharma Solutions business for $4.25 billion in cash to focus on core operations and reduce interest expenses [4] - A standalone kidney care company, Vantive, is expected to be formed by July 2024, comprising the Renal Care and Acute Therapies product categories [4] Regulatory Developments - Baxter received FDA approval for an expanded indication for Clinolipid to be used in pediatric patients, including preterm and term neonates [6] - The company launched five new injectable products in the U.S. to enhance its pharmaceutical portfolio, which are expected to meet patient needs and provide convenience for healthcare professionals [6] Challenges - Despite recovery, Baxter faces ongoing pressure related to hospital admissions and procedural volumes, with supply chain disruptions impacting growth [7] - The APAC market contributes nearly 17% to Baxter's revenues, with China representing a significant growth opportunity, although challenging market dynamics may affect the company's performance in the region [7] Financial Estimates - The Zacks Consensus Estimate for 2024 revenues is $15.11 billion, indicating a 1.1% decline from the previous year, but revenues are expected to grow by 4% [8] - The consensus estimate for adjusted EPS is $2.91, reflecting an 11.9% increase from the previous year, with a 0.7% improvement in estimates over the past 30 days [8]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are t ...

Company Overview - Baxter International Inc. received FDA approval for an expanded indication for Clinolipid, allowing its use in pediatric patients, including preterm and term neonates, which is expected to enhance its Infusion Therapies and Technologies product line [1] - Clinolipid has been available for adults since 2019 and is now accessible for all age groups, indicating a significant expansion of its market reach [1] Significance of the Approval - Parenteral nutrition is crucial for treating malnutrition, with Baxter estimating that around 40% of patients receiving parenteral nutrition in the U.S. are under 18 years old [2] - Clinolipid is Baxter's proprietary mixed oil lipid emulsion, providing essential calories and fatty acids when oral or enteral nutrition is not feasible [2] - The expanded access to Clinolipid is expected to offer clinicians more options tailored to the needs of vulnerable pediatric patients [2] Industry Prospects - The global clinical nutrition market was valued at approximately $38 billion in 2023 and is projected to exceed $70.33 billion by 2032, growing at a CAGR of 6.4% [3] - Factors driving this growth include the rising incidence of chronic diseases, increased use of clinical nutritional products, and heightened concerns about pediatric malnutrition [3] - The FDA's approval for Clinolipid is anticipated to significantly benefit Baxter's business within this expanding market [3] Recent Developments - Baxter reported mid-single-digit growth in its Medical Products & Therapies segment for Q1 2024, attributed to positive demand and pricing [4] - The company also received FDA 510(k) clearance for its Novum IQ large-volume infusion pump with Dose IQ Safety Software, indicating ongoing innovation [4] Price Performance - Baxter's shares have declined by 17.3% over the past year, contrasting with a 3.5% decline in the industry and a 26.5% increase in the S&P 500 [5]

Baxter International (BAX) reported $3.59 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 1.6%. EPS of $0.65 for the same period compares to $0.59 a year ago.The reported revenue represents a surprise of +1.20% over the Zacks Consensus Estimate of $3.55 billion. With the consensus EPS estimate being $0.61, the EPS surprise was +6.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

FI RS T-Q UA RT ER 2024 EA RNI NGS Baxter International Inc. May 2, 2024 1 FORWA R D- LOOKING STAT EM ENT S ...

Baxter International Inc. (NYSE:BAX) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Clare Trachtman - Vice President, Investor Relations Joe Almeida - Chairman & Chief Executive Officer Joel Grade - Executive Vice President & Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Danielle Antalffy - UBS Patrick Wood - Morgan Stanley Travis Steed - Bank of America ...

Baxter International (BAX) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.56%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.86 per share when it actually produced earnings of $0.88, delivering a surprise of 2.33%.Over the last fou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2024 RESULTS DEERFIELD, Ill., MAY 2, 2024 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024. "Baxter's results in the first quarter reflect the company's solid operational performance, fueled by the benefits being realized from our ongoing strategic transformation initiatives, including our new operating model structure, and continued strong execution across our integrated supp ...

Analysts on Wall Street project that Baxter International (BAX) will announce quarterly earnings of $0.61 per share in its forthcoming report, representing an increase of 3.4% year over year. Revenues are projected to reach $3.55 billion, declining 2.7% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a ...